Every 10-Q that Profound Medical Corp. (PROF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PROF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PROF filings page.
Profound Medical Corp. reported revenue of $7,820 (USD in thousands) for the six months ended June 30, 2026, up from $4,832 a year earlier, driven by higher capital equipment sales and recurring non‑capital revenue. Gross profit rose to $5,779 from $3,471, while operating expenses declined to $24,866 from $28,443, narrowing the net loss to $16,593 from $26,419; basic and diluted loss per share improved to $0.46 from $0.88.
Research and development spending was stable at $10,916 for the six‑month period, while selling, general and administrative expenses decreased to $13,950 from $17,537 as the company reduced salaries and commissions, travel, consulting fees and insurance costs. Cash was $38,271 at June 30, 2026 compared with $59,723 at December 31, 2025, after $19,921 of net cash used in operating activities; a $4,507 balance on the CIBC revolving credit facility was classified as current. Management states that existing cash and product and service sales are expected to fund operating and capital needs for at least the next 12 months and confirms compliance with financial covenants under the CIBC Credit Agreement.
Profound Medical Corp. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $5,337 from $2,621 a year earlier, driven by higher capital equipment sales and recurring device revenue, while gross margin held near 72%.
Operating expenses fell to $11,853 from $13,019, narrowing the net loss to $7,053 from $10,724, or $0.19 per share versus $0.36. Cash declined to $50,295 from $59,723 at December 31, 2025, mainly from operating use of cash, and management believes current cash and product sales can fund operations for at least 12 months.
Profound Medical Corp. reported Q3 2025 results and highlighted liquidity risks. Revenue rose to $5.289 million, up 87% year over year, driven by U.S. capital sales and higher recurring revenue. Gross margin improved to 74% from 63% as manufacturing efficiency and mix shifted toward higher‑margin systems. Net loss was $7.977 million, narrowing from $9.365 million.
For the nine months ended September 30, 2025, revenue was $10.121 million and net loss totaled $34.395 million, with operating cash outflow of $31.641 million. Cash was $24.826 million and working capital was $31.586 million as of September 30, 2025. Long‑term debt was presented as current at $4.480 million due to a projected covenant breach by June 30, 2026 under the CIBC Credit Agreement. Management disclosed substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing. As of November 13, 2025, 30,193,592 common shares were outstanding.
The company continues remediation of a previously identified material weakness in revenue recognition controls.